Pembrolizumab-Induced Myocarditis and Delayed Acute Inflammatory Demyelinating Polyradiculoneuropathy

Pembrolizumab is an immunotherapeutic agent used in various malignancies including metastatic melanoma. While immunotherapies are effective in treating several malignancies, they do come at the expense of inadvertent side effects. The numerous side effects of pembrolizumab, including, but not limite...

Descripción completa

Detalles Bibliográficos
Autores principales: Dalal, Fazal, Dalal, Hussain, Baltz, Brad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392481/
https://www.ncbi.nlm.nih.gov/pubmed/36004023
http://dx.doi.org/10.7759/cureus.27112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392481/
https://www.ncbi.nlm.nih.gov/pubmed/36004023
http://dx.doi.org/10.7759/cureus.27112

Ejemplares similares